COMPUGEN LTD

Compugen Ltd. announced its 2026 Annual General Meeting of Shareholders will be held on September 10, 2026, in Holon, Israel. Key agenda items include the election of eight directors, approval of the Amended Compensation Policy, and the re-appointment of Kost Forer Gabbay & Kasierer as the independent registered public accounting firm for fiscal year 2026. Shareholders will also have an opportunity to discuss the audited consolidated financial statements for the fiscal year ended December 31, 2025.

Compugen Ltd. reported its second quarter 2026 financial results, with revenues increasing to $2.6 million from $1.3 million in the comparable period of 2025, and net loss narrowing to $7.0 million from $7.3 million. The company provided positive updates on its clinical pipeline, including the MAIA-ovarian trial for COM701 progressing as planned with interim analysis data expected by Q1 2027. Partnered programs with AstraZeneca and Gilead also advanced, and Compugen maintains a strong financial position with a cash runway expected to fund operations into 2029.

Compugen reported a net loss of $7.7 million, or $0.08 per share, on revenues of $2.2 million for the first quarter of 2026. This compares to a net loss of $7.2 million and revenues of $2.3 million in the prior year period. The company highlighted continued progress across its clinical programs, including active enrollment in the COM701 MAIA-ovarian trial and AstraZeneca's advancement of rilvegostomig in 11 Phase 3 trials. Compugen maintains a solid financial position with a cash runway expected to fund operations into 2029.